Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 5 art units • 7 examiners • 0 of 8 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Akouos, Inc. has 7 pending office actions, involving 7 distinct examiners and 5 distinct art units in Biotechnology & Pharmaceuticals. Every listed action has a different examiner, while the art-unit total indicates that some units handle more than one matter.
SINGH, ANOOP KUMAR is identified as the busiest examiner, with 1 pending matter. The portfolio requires coordination across 5 art units and separate examiner-focused response work.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 4 (50%) |
| Double-patenting + other | 2 (25%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SINGH, ANOOP KUMAR | 2 | 43.2% | +67.7% |
| POHNERT, STEVEN C | 1 | 12.5% | +18.2% |
| REGLAS, GILLIAN CHELSEA | 1 | 32.3% | +37.5% |
| JACKSON III, WALTER | 1 | 50.0% | +0.0% |
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| MCLEOD, AFRICA MHAIRIE | 1 | 52.8% | +67.7% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19034863 | AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR | POHNERT, STEVEN C | 8d |
| 19254653 | ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS | SINGH, ANOOP KUMAR | — |
| 17923636 | COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS | VIVLEMORE, TRACY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19034863 | AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR | POHNERT, STEVEN C | 8d |
| 17998486 | COMPOSITIONS AND METHODS FOR TREATING GJB2-ASSOCIATED HEARING LOSS | MCLEOD, AFRICA MHAIRIE | 9d |
| 18806641 | USE OF ADENO-ASSOCIATED VIRAL VECTORS TO CORRECT GENE DEFECTS/ EXPRESS PROTEINS IN HAIR CELLS AND SUPPORTING CELLS IN THE INNER EAR | REGLAS, GILLIAN CHELSEA | 54d |
| 19254653 | ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS | SINGH, ANOOP KUMAR | — |
| 19095919 | ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS | SINGH, ANOOP KUMAR | — |
| 18269307 | COMPOSITIONS AND METHODS FOR TREATING CLRN1-ASSOCIATED HEARING LOSS AND/OR VISION LOSS | ALLEN, MICHAEL D | — |
| Art Unit | Apps |
|---|---|
| 1632 | 3 |
| 1638 | 2 |
| 1683 | 1 |
| 1671 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19254653 | ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS | SINGH, ANOOP KUMAR | 1632 | §103§112Other | Final Rejection | — | Pending | Jun 30, 2025 |
| 19095919 | ANTI-VEGF ANTIBODY CONSTRUCTS AND RELATED METHODS FOR TREATING VESTIBULAR SCHWANNOMA ASSOCIATED SYMPTOMS | SINGH, ANOOP KUMAR | 1632 | §103§112DP | Final Rejection | — | Pending | Mar 31, 2025 |
| 19034863 | AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR | POHNERT, STEVEN C | 1683 | §103 | Final Rejection | 8d | Pending | Jan 23, 2025 |
| 18806641 | USE OF ADENO-ASSOCIATED VIRAL VECTORS TO CORRECT GENE DEFECTS/ EXPRESS PROTEINS IN HAIR CELLS AND SUPPORTING CELLS IN THE INNER EAR | REGLAS, GILLIAN CHELSEA | 1632 | §103 | Final Rejection | 54d | Pending | Aug 15, 2024 |
| 18696131 | COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS | JACKSON III, WALTER | 1638 | §103 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18269307 | COMPOSITIONS AND METHODS FOR TREATING CLRN1-ASSOCIATED HEARING LOSS AND/OR VISION LOSS | ALLEN, MICHAEL D | 1671 | §103 | Non-Final OA | — | Pending | Jun 23, 2023 |
| 17998486 | COMPOSITIONS AND METHODS FOR TREATING GJB2-ASSOCIATED HEARING LOSS | MCLEOD, AFRICA MHAIRIE | 1635 | §103DP | Final Rejection | 9d | Pending | Nov 10, 2022 |
| 17923636 | COMPOSITIONS AND METHODS FOR TREATING KCNQ4-ASSOCIATED HEARING LOSS | VIVLEMORE, TRACY ANN | 1638 | §101§103§112 | Final Rejection | — | Pending | Nov 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAkouos, Inc. has 8 pending office actions as of October 2026, spread across 5 art units and 7 examiners.
Anoop Kumar Singh has the most, with 2 of Akouos, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
